Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The authors evaluated 138 patients with superficial bladder tumors initially ... the 35 patients who received intravesical BCG therapy (mean 8 instillations, range 1–20) had markedly improved ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

BCG is also used as a biotherapy for superficial bladder carcinoma. Despite being the most successful cancer biotherapy, the mechanism of action and determinants of response to BCG remain obscure. We ...

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

Originally used as a tuberculosis vaccine, BCG administered via intravesical instillation (delivery to the bladder via a catheter) has been the standard of care for patients with non-muscle ...

BCG given via intravesical instillation (delivery to the bladder via a catheter) has been the standard of care for patients with non-muscle invasive bladder cancer (NMIBC) since 1977. BCG induces ...

The treatment of choice for superficial (non muscle-invasive) bladder cancer is cystoscopic resection followed by intra-vesical instillations of BCG. Although it is the most successful treatment for ...

SAN ANTONIO -- More than 70% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) achieved complete responses to a novel gene therapy, a small preliminary trial showed.